UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 | --- | --- | |---------------------------------------------------------------------------------|----------------------------------------| | Clearside Biomedi ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Jenny Kobin - Head of Investor Relations George Lasezkay - President, Chief Executive Officer Thomas Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - Chief Financial Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Partners, LLC Annabel Samimy - Stifel, Nicolaus & Company, Inc. Andreas Argyrides - Wedbush Securities Inc. Serge Belanger - Needha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Emerging growth company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2437375 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to __________ Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2437375 (State ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2020 Earnings Conference Call March 10, 2021 4:30 PM ET Company Participants Jenny Kobin - Head, IR George Lasezkay - President and CEO Thomas Ciulla - CMO and Chief Development Officer Charles Deignan - CFO Conference Call Participants Andreas Argyrides - Wedbush Securities Annabel Samimy - Stifel Jonathan Wolleben - JMP Securities Operator Greetings, and welcome to the Clearside Biomedical Fourth Quarter and Year-End Financial Results and Corporate Update Confer ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Jenny Kobin - Head, Investor Relations George Lasezkay - President & Chief Executive Officer Thomas Ciulla - Chief Medical Officer & Chief Development Officer Charles Deignan - Chief Financial Officer Conference Call Participants Zegbeh Jallah - Roth Capital Partners Annabel Samimy - Stifle Jonathan Wolleben - JMP Securities Operator Ladies and gentlemen thank you standing by and welco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------|----- ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Jenny Kobin - Head, Investor Relations George Lasezkay - President & Chief Executive Officer Thomas Ciulla - Chief Medical Officer & Chief Development Officer Charles Deignan - Chief Financial Officer Conference Call Participants Boris Peaker - Cowen Jonathan Wolleben - JMP Securities Zegbeh Jallah - Roth Capital Partners Operator Good afternoon ladies and gentlemen and welcome to the Cl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------|---------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 | --- | --- | |-------------------------------------------------------------------------------------------------------------------------|-------------------- ...